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Abstract
The intracellular bacterium Chlamydia trachomatis causes infections of urogenital tract, eyes or lungs. Alignment reveals
homology of CT166, a putative effector protein of urogenital C. trachomatis serovars, with the N-terminal
glucosyltransferase domain of clostridial glucosylating toxins (CGTs). CGTs contain an essential DXD-motif and mono-
glucosylate GTP-binding proteins of the Rho/Ras families, the master regulators of the actin cytoskeleton. CT166 is
preformed in elementary bodies of C. trachomatis D and is detected in the host-cell shortly after infection. Infection with
high MOI of C. trachomatis serovar D containing the CT166 ORF induces actin re-organization resulting in cell rounding and
a decreased cell diameter. A comparable phenotype was observed in HeLa cells treated with the Rho-GTPase-glucosylating
Toxin B from Clostridium difficile (TcdB) or HeLa cells ectopically expressing CT166. CT166 with a mutated DXD-motif (CT166-
mut) exhibited almost unchanged actin dynamics, suggesting that CT166-induced actin re-organization depends on the
glucosyltransferase motif of CT166. The cytotoxic necrotizing factor 1 (CNF1) from E. coli deamidates and thereby activates
Rho-GTPases and transiently protects them against TcdB-induced glucosylation. CNF1-treated cells were found to be
protected from TcdB- and CT166-induced actin re-organization. CNF1 treatment as well as ectopic expression of non-
glucosylable Rac1-G12V, but not RhoA-G14A, reverted CT166-induced actin re-organization, suggesting that CT166-induced
actin re-organization depends on the glucosylation of Rac1. In accordance, over-expression of CT166-mut diminished TcdB
induced cell rounding, suggesting shared substrates. Cell rounding induced by high MOI infection with C. trachomatis D was
reduced in cells expressing CT166-mut or Rac1-G12V, and in CNF1 treated cells. These observations indicate that the
cytopathic effect of C. trachomatis D is mediated by CT166 induced Rac1 glucosylation. Finally, chlamydial uptake was
impaired in CT166 over-expressing cells. Our data strongly suggest CT166’s participation as an effector protein during host-
cell entry, ensuring a balanced uptake into host-cells by interfering with Rac-dependent cytoskeletal changes.
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Introduction
Chlamydia trachomatis is a gram negative, obligate intracellular
bacterium. It causes infections of the eyes, the urogenital tract, or
the lungs of newborns. Infections with the serovars D–K range
from acute to chronic inflammatory diseases of the urogenital tract
with sequelae such as infertility or reactive arthritis. The serovars
L1–L3 cause Lymphogranuloma venereum, a more severe sexually
transmitted urogenital infection that also affects the inguinal
lymph nodes. Serovars A–C lead to trachoma, the main cause of
preventable blindness worldwide.
Chlamydiae share a unique developmental cycle: A metabolically
inactive, infectious form called the elementary body (EB) enters
the host-cell. In a host-derived inclusion it differentiates into its
metabolically active form called the reticulate body that multiplies
by binary fission. Approximately 20 h post infection (p.i.), the
reticulate bodies start to differentiate back into a new generation of
infectious EBs.
The ‘‘plasticity zone’’[1]in the genome of the serovars D–K, and
of C. muridarum (a pathogen of mice) and C. caviae (a pathogen of
guinea pig) contains an open reading frame (ORF) with sequence
similarities at the amino acid level to bacterial and mammalian
glucosyltransferases [2,3]. Protein database alignment revealed
homology of the N-terminal glucosyltransferase domain of clostrid-
ial glucosylating toxins (CGTs) to CT166 [4], the 1917 bp ORF of
C. trachomatis serovar D [5]. The essential structural element for
the glucosyltransferase activity in the clostridial enzymes is a motif
containing the amino acid sequence DXD, which is involved in
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9887Mn
2+-dependent binding of UDP-glucose in the catalytic cleft [3].
Mutational exchange of both aspartic acid residues into alanines
strongly reduces enzymatic activity [3,6].
The CGT glucosyltransferases mono-glucosylate specifically low
molecular weight GTP-binding proteins of the Rho/Ras families
[7,8]. The Rho proteins are master regulators of the actin
cytoskeleton that cycle between a GTP-bound active conformation
and a GDP-bound inactive conformation [9]. CGT-catalyzed
glucosylation prevents activation of Rho/Ras proteins, leading to
inhibited effector coupling and subsequent breakdown of the actin
cytoskeleton of the target cell (‘‘cytopathic effect’’).
So far, it has only been shown that the hypothetical protein
CT166 is actually expressed by C. trachomatis serovar D [2]: The
protein can be detected in elementary bodies. Additionally, during
the first 60 min p.i. it is present in lysates of epithelial HeLa cells
that were incubated with high multiplicities of infection (MOIs) of
serovar D. Infection with C. trachomatis D (but not L2 lacking the
corresponding ORF) leads to actin re-organization and cell
rounding. These findings led to the hypothesis that CT166 is a
glucosyltransferase that possibly inactivates Rho proteins and
subsequently causes actin re-organization.
In this study, we analyzed the biochemical and functional
potential of CT166 using HeLa cells that ectopically express this
putative glucosyltransferase or the corresponding protein with
mutated DXD-motif. Our data show that CT166 induces actin re-
organization similar to that observed upon high MOI infection of
HeLa cells with C. trachomatis D. Our results indicate that CT166
acts on the level of Rho-proteins and suggest that glucosylation of
Rac1 by CT166 might be the underlying mechanism leading to
actin re-organization.
Results
Actin Re-organization Induced by CT166-containing
C. trachomatis Serovar D Resembles That Induced by
C. difficile Toxin B
C. trachomatis D exhibits the CT166 ORF, a putative
glucosyltransferase. To corroborate the hypothesis that CT166
induces actin re-organization HeLa cells were infected with C.
trachomatis D and analyzed for actin re-organization. Infection with
the CT166-proficient C. trachomatis D caused a loss of actin stress
fibers and a loss of cell shape (cell rounding), as analyzed using
phase contrast microscopy and fluorescence microscopy of
rhodamine-phalloidin-stained cells (Figure 1). Comparable mor-
phological changes were observed upon treatment of HeLa cells
with the Rho-glucosylating C. difficile Toxin B (TcdB) (Figure 1).
Infection of HeLa cells with the C. trachomatis L2 that lacks the
CT166 ORF did not cause actin re-organization of HeLa cells
(Figure 1), suggesting that C. trachomatis D-induced actin re-
organization depends on CT166.
Expression of CT166 in E. coli and Generation of Specific
Antiserum
Following the hypothesis that CT166 is a glucosyltransferase,
CT166 and a corresponding DXD-mutant CT166-
D415A.D417A (CT166-mut) were expressed as GST fusion
proteins in E. coli, an approach that has been successfully applied
for the characterization of the catalytic properties of TcdB and
other glucosylating toxins [3,4,10]. Recombinant CT166 was
analyzed for glucosyltransferase activity and for glucohydrolase
activity in the presence of several [
14C]-labeled UDP-hexoses
including UDP-glucose, UDP-galactose, and UDP-N-acetylgluco-
samin. Unfortunately, CT166 expressed by E. coli exhibited
neither glucosyltransferase nor glucohydrolase activity (data not
shown). Affinity purified CT166-mut, however, was applied as
antigen to raise anti-CT166 antiserum in rabbits (see Figure S1A
and B).
Generation of CT166 Expressing HeLa Clones
In order to generate a tool to analyze CT166 functions, CT166-
wt and CT166-mut were expressed in HeLa cells, using a
tetracycline-inducible expression system (TREx
TM System, Invi-
trogen). Several HeLa clones were analyzed for expression of
CT166-wt and CT166-mut using Western blot analysis with anti-
CT166 antiserum (Figure S1A). Upon treatment with 1 mg/ml
tetracycline all analyzed HeLa clones expressed either CT166-wt
or CT166-mut. These myc-tagged proteins exhibited an apparent
molecular mass of approximately 75 kDa, in good accordance
with the calculated molecular mass of ,77 kDa.
Figure S1A exemplarily presents the expression in two sets of
HeLa clones, each containing one CT166-wt or CT166-mut ex-
pressing clone and a corresponding control: HeLa-CT166-wt_JT30,
Figure 1. C. trachomatis serovar D causes actin re-organization and cell rounding comparable to Toxin B from C. difficile (TcdB), while
the CT166 ORF lacking C. trachomatis serovar L2 does not. HeLa cells were mock treated, or treated with C. trachomatis D, C. trachomatis L2
(MOI 100) or TcdB (1 ng/ml for 2 h). Cells were fixed 4 h post infection and the actin cytoskeleton was stained with rhodamine-phalloidin.
doi:10.1371/journal.pone.0009887.g001
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CT166-wt_JT26, HeLa-CT166-mut_JTB4, and HeLa-control_JT1
(set 2). Within each set the cellular concentrations of CT166-wt and
CT166-mut were in a similar range, as normalized to total protein
concentration or b-actin concentration. The HeLa clones from set 1
were used for all following experiments, if not indicated otherwise. A
fivefold increased tetracycline concentration did not further augment
the cellular CT166 concentration (Figure S1B). Some CT166
expression, however, was also observed in the absence of tetracycline
(Figure S1B) showing that CT166 expression was thus not completely
repressed. CT166 expression was further analyzed by immuno-
cytochemistry using anti-myc antibody. HeLa-CT166-wt and HeLa-
CT166-mut cells(upontetracyclinetreatment) stained positiveforthe
myc-tagged proteins in the cytosol (Figure S2). HeLa-control cells
(that lacked CT166 expression) showed a slight positive staining that
predominantly located to the nucleus, most likely resulting from
endogenous myc (Figure S2).
HeLa-CT166-wt cells exhibited a reduced proliferation rate
compared to HeLa-control or HeLa-CT166-mut cells (Figure 2),
as analyzed in the presence of tetracycline. This finding suggested
that CT166-wt expression interfered with cell cycle progression. In
contrast, HeLa-CT166-mut exhibited a doubling time comparable
to HeLa-control cells (Figure 2). The finding of a reduced
proliferation rate suggests a critical role of the DXD-motif in the
CT166 activity on cell proliferation.
Critical Role of the DXD-motif in CT166-induced Actin Re-
organization of HeLa Cells
To corroborate the hypothesis that CT166 is responsible for
actin re-organization induced by C. trachomatis D (Figure 1), the
actin cytoskeleton of several HeLa-CT166-wt and HeLa-CT166-
mut clones was visualized using rhodamine-conjugated phalloidin.
Expression of CT166-wt resulted in the disappearance of actin
stress fibers and loss of cell shape (cell rounding) in several clones
of HeLa-CT166-wt (Figures 3A and S1C). This morphological
outcome was comparable to that upon infection of HeLa cells with
C. trachomatis D or comparable to treatment of HeLa cells with
TcdB (Figure 1). CT166-induced actin re-organization was
quantified. Cells exhibiting a cell diameter less than 30 mm were
classified as ‘‘rounded’’ (‘‘cytopathic effect’’, Figures 3B and S1D).
About 70% of all HeLa-CT166-wt cells were rounded, while only
about 9% of HeLa-control cells exhibited this phenotype
(Figures 3B and S1D). The increased cytopathic effect was
reflected by a reduced average diameter of these cells (Figures 3C
and S1E). The cytopathic effect in HeLa-CT166-wt cells was
independent of tetracycline treatment (Figures 3B, 3C, S1D and
S1E), suggesting that low CT166 expression in HeLa-CT166-wt
cells as observed in the absence of tetracycline (Figure S1B) was
already sufficient for the maximal cytopathic effect. This is
consistent with the hypothesis that CT166 acts as an enzyme with
high biological potential. Actin re-organization was further
analyzed in several clones of HeLa-CT166-mut cells (Figure 3).
All clones of these cells exhibited minor morphological changes
compared to HeLa-CT166-wt cells including a partial loss of stress
fibers, a less pronounced cytopathic effect and a higher (i.e. less
reduced) average cell diameter (Figure 3). This observation
suggests that CT166-mut is not a ‘‘dead’’ enzyme but still exhibits
a faint catalytic activity. Such a faint catalytic activity that resulted
in minor morphological changes has recently been described for
the Rho/Ras-glucosylating C. sordellii Lethal toxin (TcsL) with
mutated DXD-motif [6].
In the T-Rex expression system, CT166 and the corresponding
mutant are tagged at the C-terminus. To confirm the findings
obtained with the stably transfected HeLa cell lines and to further
exclude clonal artifacts, we generated constructs for transient
expression of N-terminal 6x-c-myc-tagged fusion proteins of
CT166-wt and CT166-mut. Successful expression of the myc-
tagged proteins was visualized by immuno-cytochemistry using
anti-myc antibody (Figure S3). Transient expression of CT166-wt
(but not CT166-mut) induced actin re-organization comparable to
that observed in HeLa-CT166-wt cells. As expected, transient
transfection resulted in distinct CT166 concentrations in each
individual cell, as estimated from different fluorescence intensities
(Figure S3). Regardless of these distinct cellular concentrations of
CT166-wt all cells exhibited actin re-organization (cell rounding),
showing that relatively low concentrations of CT166-wt were
sufficient for the induction of actin re-organization. In contrast,
even cells expressing high amounts of CT166-mut did not show
the same rounded phenotype as CT166-wt transfected cells. These
observations confirmed that CT166-wt was sufficient for actin re-
organization and that the DXD-motif was critical for the
cytopathic activity of CT166.
Possible Role of the Rho-family Protein Rac1 in
CT166-induced Actin Re-organization
Rho proteins are susceptible to TcdB-catalyzed glucosylation
specifically in their inactive GDP-bound state. In their GTP-
bound state, the acceptor amino acid (Thr-35 in Rac1, Thr-37 in
RhoA) is involved in GTP coordination and therefore not
accessible for glucosylation; active Rho proteins are thus protected
from glucosylation [11–13].
Based on the assumption that CT166-induced actin re-
organization is mediated by glucosylation of Rho proteins,
activation of Rho proteins should prevent CT166-induced actin
re-organization. Rho proteins were activated using the cytotoxic
necrotizing factor 1 (CNF1) from E. coli, that deamidates and
thereby constitutively activates a broad-spectrum of Rho proteins
[14,15]. CNF1 treatment of HeLa cells prevented TcdB-induced
actin re-organization in HeLa cells (Figure S4), corroborating
published data [16]. CNF1 treatment of HeLa-CT166-wt cells
induced stress fiber formation and rounded cells spread out
Figure 2. Expression of CT166 reduces proliferation rate of
HeLa cells. Proliferation of HeLa-CT166-wt and HeLa-CT166-mut and
non-expressing control cells, in the presence of tetracycline, was
monitored by fluorescence staining of the DNA with Hoechst 33258 as
described in ‘‘Material and Methods’’. The CT166-mutant expressing
cells (#) show a growth similar to non-expressing cells (D). The growth
of CT166-wildtype expressing cells (N) is considerably diminished. The
mean 6 SD of three independent experiments is depicted.
doi:10.1371/journal.pone.0009887.g002
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sufficient to prevent CT166-induced actin re-organization (‘‘pro-
tective effect’’). The treatment of HeLa-CT166-wt with CNF1 did
not interfere with the ectopic expression of CT166, as the cellular
CT166 level was comparable in the presence or absence of CNF1
(Figure S5A), excluding the possibility that the reduction in cell
rounding was based on reduced CT166 expression. These
observations suggested that Rho proteins may be targets of
CT166.
To show a critical role of Rho proteins in CT166-induced actin
re-organization, constitutively active Rac1-G12V and Rac1-wild-
type (Rac1-wt) were transiently transfected into HeLa-CT166-wt
cells. The actin cytoskeleton was analyzed in HeLa-CT166-wt cells
expressing EGFP-tagged Rac1-G12V or Rac1-wt (Figure 5).
Expression of Rac1-wt moderately reduced CT166-induced cell
rounding (Figure 5). By contrast, Rac1-G12V, that is refractory to
glucosylation by TcdB [11], almost completely prevented CT166-
induced actin re-organization (Figures 5A and B) and the decrease
of the average cell diameter (Figure 5C). Expression of either
Rac1-G12V or Rac1-wt did not interfere with CT166 expression
Figure 4. CNF1 reverts the CT166-induced phenotype. HeLa-
CT166-wt, HeLa-CT166-mut and HeLa-control cells were treated with
tetracycline for 24 h and subsequently treated with 0.1 mg/ml CNF1
from E. coli for 6 h. Actin cytoskeleton was stained with rhodamine-
phalloidin. One representative experiment (n=3) is depicted.
doi:10.1371/journal.pone.0009887.g004
Figure 3. Cytopathic effect in HeLa cells stably expressing
CT166 (but no multi-nucleation). HeLa-CT166-wt, HeLa-CT166-mut
and HeLa-control cells were stained with rhodamine-phalloidin and
DAPI after 24 h incubation with 1 mg/ml tetracycline. (A). Rounded cells
(cell diameter ,30 mm) were quantified by microscopy and given as
ratio in percent. Comparison of untreated and tetracycline-treated HeLa
clones reveals similar results (B). The average cell diameter was
determined (C). Depicted is the mean 6 SD of three independent
experiments. (** indicates significant difference as compared to control
cells, p,0.005.)
doi:10.1371/journal.pone.0009887.g003
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comparable in the presence or absence of Rac1-G12V (Figure
S5B). The difference in the protective effect of either Rac1-wt or
Rac1-G12V supports the hypothesis that CT166 glucosylates Rho
proteins, in particular Rac1: Ectopically expressed Rac1-wt can be
glucosylated and is thus not capable of preserving Rac1 activity as
efficaciously as the ectopically expressed non-glucosylable Rac1-
G12V, an observation also reported for TcdB-catalyzed Rac1
glucosylation [13].
Next, the cellular level of Rac1 was analyzed in HeLa-CT166-
wt, HeLa-CT166-mut and in HeLa-control cells by Western
blotting using anti-Rac1 (Mab23A8), which has been reported to
be unaffected in its antigen recognition by the glucosylation state
of Rac1. The Rac1 level was reduced in HeLa-CT166-wt cells
compared to HeLa-CT166-mut and HeLa-control cells (Figure 6).
This reduced Rac1 level impeded to directly check for CT166-
induced Rac1 glucosylation at Thr-35 using the glucosylation-
sensitive Rac1 antibody clone 102 [17]. The reduced Rac1 level
may support the hypothesis that Rac1 is targeted by CT166.
Degradation of Rho proteins has been suggested to represent a
cellular response to limit cytotoxicity induced by toxin-catalyzed
covalent modifications of Rho proteins [18]. In this line, RhoA
degradation has been reported upon mono-ADP-ribosylation by
C3-bot [19] or upon mono-glucosylation by TcdB [17]. It thus
appears to be plausible that Rac1 (possibly covalently modified
by CT166) was degraded in HeLa-CT166-wt cells. Treatment of
Figure 5. Expression of a constitutive active Rac1 mutant and over-expressed Rac1 reverts the CT166-induced phenotype. HeLa-
CT166-wt, HeLa-CT166-mut and HeLa-control cells were transiently transfected with the pEGFP-C1 vector encoding for human Rac1-G12V or Rac1-wt,
RhoA-G14V or RhoA-wt, respectively. The rhodamine-phalloidin stained actin cytoskeleton and expression of GFP-fusion protein were visualized by
fluorescence microscopy (A). Rounded GFP-positive cells (cell diameter ,30 mm) were quantified and given as the ratio of rounded per total GFP-
positive cells in percent (** indicates significant less rounded cells as compared to control cells, p,0.005) (B). The average cell diameter of GFP-
positive cells was determined (*/** indicates significant increase as compared to control cells, p,0.05/p,0.005) (C). Depicted is the mean 6 SD of
three independent experiments.
doi:10.1371/journal.pone.0009887.g005
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resulted in cell death (unpublished observation) impeding further
analysis.
CT166-induced actin re-organization and cell rounding was not
prevented by ectopic expression of RhoA-G14V or RhoA-wildtype
(Figure 5). This observation likely excludes a critical role of RhoA in
CT166-induced actin re-organization. To check if CT166 targeted
RhoA, the cellular level of RhoA was tracked by either Western blot
analysis or sequential [
32P]ADP-ribosylation of RhoA catalyzed by
C3-bot [20]. The RhoA level was increased in HeLa-CT166-wt
cells (less pronounced in HeLa-CT166-mut cells) compared to
HeLa-control cells, as evidenced by either method (Figure 6). This
observation likely excluded that RhoA from HeLa-CT166-wt cells
was glucosylated at Thr-37, as RhoA glucosylation at Thr-37 would
have caused decreased ADP-ribosylation of RhoA at Asn-41 [20].
Moreover, CT166-induced RhoA inactivation (e.g. by glucosyla-
tion) in HeLa-CT166-wt cells was also unlikely, for the reason that
RhoAiscriticalforcontractileringformationincytokinesisand thus
critical for cell proliferation [21]. RhoA inactivation would have
resulted in multinucleated cells (indicative of cytokinesis inhibition),
which was not observed (Figure 3A).
If CT166 targets Rac1, this targeting most likely includes first
binding of the substrate Rac1 (and other possible substrate
proteins from the Rho subfamily) to CT166. Binding of CT166-
mut to Rho proteins may preserve substrate glucosylation by
bacterial CT166 upon infection, and thus, may subsequently
preserve actin re-organization induced by C. trachomatis D. HeLa-
CT166-mut cells should thus exhibit a lower sensitivity to C.
trachomatis D-induced actin re-organization compared to HeLa-
control cells. This was in fact observed (Figure 7). These
observations suggested that CT166-mut binds the CT166
substrate proteins from the Rho family and preserves them from
CT166-induced glucosylation upon C. trachomatis D infection.
Based on the assumption that CT166-mut binds cellular Rho
proteins, HeLa-CT166-mut cells should also exhibit a lower
sensitivity to TcdB-induced actin re-organization, through the
preservation of Rho proteins from TcdB-induced glucosylation.
And indeed, this was observed (Figure 8). The lower sensitivity of
HeLa-CT166-mut cells was transient, as it was only observed after
short-time treatment (2 h) with TcdB. After prolonged treatment
(4 h) with TcdB the complete population of HeLa-CT166-mut
cells was rounded (data not shown), likely due to the release of Rho
proteins from the CT166-mut complex.
To finally provide evidence on an involvement of Rac1 in actin re-
organization upon C. trachomatis D infection, actin re-organization
induced by this serovar was analyzed in HeLa cells transfected with
either GFP-tagged Rac1-G12V or the empty control vector.
Consistent with above observation from HeLa-CT166-wt cells
(Figure 5), expression of Rac1-G12V protected HeLa cells against
C. trachomatis D-induced actin re-organization (Figure 9A, B, C).
T h e s ef i n d i n g sc o n f i r mt h ec r i t i c a lr o l eo fR a c 1i nC. trachomatis D-
induced actin re-organization. HeLa cells that were pre-treated with
CNF1 were also protected from C. trachomatis D-induced actin re-
organizationascomparedtobuffer-treatedcells(Figure9D,E).These
observations suggest that the C. trachomatis D-induced actin re-
organization ismediated by inactivation of the targeted Rho-proteins.
CT166 as a Negative Regulator of Chlamydial Uptake into
HeLa Cells
Rac1 is a key host-cell protein regulating bacterial uptake.
The bacterial effector CT166 may thus negatively regulate
the efficiency of C. trachomatis D uptake into host-cells. C. trachomatis
D infection was monitored by flow cytometry 2 h p.i. using a
FITC labeled antibody directed against chlamydial LPS. Flow
Figure 6. The Rac1 level is reduced, while RhoA is increased in
CT166 expressing HeLa cells. Cellular protein levels of RhoA and Rac1
were analyzed in tetracycline-induced (1 mg/ml for 24 h) HeLa-CT166-wt,
HeLa-CT166-mut or HeLa-control cells by Western blot analysis or
sequential [
32P]ADP-ribosylation (RhoA only). Representative Western blots
and a representative autoradiography of [32P]ADP-ribosylated RhoA are
presented (one out of three experiments with similar outcome is depicted)
(A). Signal intensities from three independent experiments were quantified
using Kodak software (B and C). The signal intensities of either RhoA or Rac1
from HeLa-control cells were set as 1.0. (* indicates statistically significant
differences as compared with HeLa-control cells, p,0.05) (B).
doi:10.1371/journal.pone.0009887.g006
CT166 - Actin Re-Organization
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9887Figure 7. C. trachomatis serovar D induced cytopathic effects
are less pronounced in CT166-mutant expressing cells. HeLa-
CT166-mut cells and HeLa-control cells were infected with C.
trachomatis D (MOI 100) or mock infected, following pre-treatment
with 1 mg/ml tetracycline for 24 h. At 2 h post infection the cytopathic
effects were less pronounced in CT166-mut expressing cells as
determined by staining of the actin cytoskeleton with rhodamine-
phalloidin (A) and by quantification of cell rounding. Rounded cells (cell
diameter ,30 mm) are given as ratio in percent (** indicates significant
differences as compared to the corresponding control cells, p,0.005)
(B). The average cell diameter was determined (** indicates significant
differences as compared to the corresponding control cells, p,0.005)
(C). Depicted is the mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0009887.g007
Figure 8. Expression of CT166-mutant delays cytopathic effects
of TcdB in HeLa cells. HeLa-CT166-mut cells and HeLa-control cells
were incubated with 1 mg/ml tetracycline for 24 h and subsequently
with 0.3 ng/ml TcdB at 37uC for 2 h. The actin cytoskeleton was stained
using rhodamine-phalloidin (A). Rounded cells (cell diameter ,30 mm)
were quantified and given as ratio in percent (** indicates significant
differences as compared to the corresponding control cells, p,0.005)
(B). The average cell diameter was determined (** indicates significant
differences as compared to the corresponding control cells, p,0.005)
(C). Depicted is the mean 6 SD of three independent experiments.
After 4 h incubation with TcdB, the HeLa-166-mut cells exhibited a
phenotype comparable to TcdB-treated control cells (not shown).
doi:10.1371/journal.pone.0009887.g008
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CNF1. HeLa cells were transiently transfected with the pEGFP-C1 vector encoding for human Rac1-G12V, or with the empty control vector. After 24 h
the cells were either mock infected or infected with C. trachomatis D (MOI 100). Depicted is the rhodamine-phalloidin staining of the actin
cytoskeleton and the fluorescence of GFP-fusion protein expressing cells at 2 h post infection (A). GFP-positive cells (cell diameter ,30 mm) were
analyzed for cell rounding (* indicates significant differences comparing mock-infected with C. trachomatis D-infected control cells, p,0.05;
** indicates significant differences comparing infected control cells with infected Rac1-G12V expressing cells, p,0.005) (B). The average cell diameter
of GFP-positive cells was determined (* indicates significant differences comparing mock-infected with C. trachomatis D-infected control cells,
p,0.05; ** indicates significant differences comparing infected control cells with infected Rac1-G12V expressing cells, p,0.005) (C). HeLa cells were
treated with 0.1 mg/ml CNF1 from E. coli for 6 h, or with buffer. Subsequently, cells were either mock infected or infected with C. trachomatis D (MOI
100). At 2 h post infection the actin cytoskeleton was stained with rhodamine-phalloidin (not shown) and rounded cells (cell diameter ,30 mm) were
quantified and given as ratio in percent (** indicates significant differences as compared to the corresponding mock-infected cells, p,0.05;
* indicates significant differences comparing infected control cells with infected CNF1-treated cells, p,0.05) (D). The average cell diameter was
determined (*/** indicates significant differences as compared to the corresponding mock-infected cells, p,0.05/p,0.005; ** indicates significant
differences comparing infected control cells with infected CNF1-treated cells, p,0.05) (E). Depicted is the mean 6 SD of three independent
experiments.
doi:10.1371/journal.pone.0009887.g009
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HeLa-CT166-wt (but not in HeLa-CT166-mut) cells compared to
HeLa-control cells (Figures 10A and S6). C. trachomatis D uptake
into HeLa-CT166-wt or HeLa-CT166-mut cells was further
analyzed using immunofluorescence microscopy after 24 h p.i.
(Figure 10B). C. trachomatis D infected almost the complete
population of HeLa-CT166-mut cells (.80% of total cells),
similar as HeLa-control cells (data not shown). In contrast, the
rate of infected HeLa-CT166-wt cells was clearly reduced (43–
47%). The rates of C. trachomatis D infection were independent of
tetracycline pre-treatment (Figure 10B), re-confirming that the low
expression of CT166-wt due to the leakiness of the gene repression
system was sufficient for the full CT166-wt activity. In course of C.
trachomatis D infection, the effector protein CT166 likely
participates in the control of C. trachomatis D uptake into host-
cells through manipulation of Rac1 activity.
Discussion
Our study is based on the observation that CT166 ORF
containing C. trachomatis strains such as serovar D cause actin re-
organization comparable to that observed upon treatment with
CGTs (Figure 1; [2]). The aim of our study was to clarify whether
CT166 causes actin re-organization similar to CT166-expressing
C. trachomatis strains and CGTs - and to elucidate the underlying
biochemical mechanism. We therefore generated CT166-express-
ing HeLa cells. Due to the limitations to perform genetic
manipulations on chlamydia, and technical problems using recom-
binant purified CT166 in a cell-free system, this is a successfully
used alternative approach for the analysis of potential chlamydial
effector proteins [22]. CT166 and CGTs share the DXD-motif,
which is critical for the glucosyltransferase activity of many
bacterial and mammalian glucosyltransferases [3,23].
Thus, we additionally generated HeLa cell lines expressing a
CT166-mutant (D415A.D417A) in order to investigate the role of
the homologue DXD-motif for CT166 function. CT166-express-
ing cells exhibited actin re-organization comparable to the CGTs
showing that CT166 alone actually has the potential to induce the
cytoskeletal effects. The DXD-motif in CT166 is critical for this
function, as the actin cytoskeleton was altered to a significantly
minor extent in HeLa-CT166-mut cells. Comparable observations
have been reported for the CGTs [3]. Similar results were
obtained using independent clones, as well as transiently
transfected cells, excluding clonal artifacts. Comparison of non-
induced low-expressing HeLa-CT166-wt clones in the leaky
repression system with strongly over-expressing tetracycline-
induced clones revealed the same results. This high biological
potential suggests an enzymatic activity of CT166. Moreover, this
observation rules out that the different phenotypes of HeLa-
CT166-wt and HeLa-CT166-mut are due to possible slight
differences in the expression levels of the recombinant proteins
(Western blot, Figure S1A).
Bacterial toxins (including bacterial effector proteins) modulate
actin dynamics by either directly targeting actin (e.g. actin ADP-
ribosylating toxins) or by targeting Rho family proteins (e.g.
glucosylating toxins or bacterial GEF or GAP proteins). The
prevention of CT166-induced actin re-organization by either
CNF1 treatment or expression of Rac1-G12V suggests that
CT166 targets Rho proteins rather than actin. This conclusion
is based on the finding that actin re-organization induced by Rho-
modulating toxins (TcdB, C3-bot), but not by actin targeting
toxins (e.g. C2 toxin or latrunculin B) is responsive to CNF1
treatment or Rac1-G12V expression [13,16,19].
Over-expressed Rac1 and expression of constitutive active
Rac1-G12V, but not RhoA and RhoA-G14V, reverted the
phenotype of HeLa-CT166-wt cells, demonstrating that active
Rac1 is sufficient to preserve cells from CT166-induced actin re-
organization. CT166 expression levels were unaffected by over-
expression of Rac proteins. We therefore conclude that CT166
inactivates Rac1, as the resulting cytopathic effect could be
compensated by increasing the amount of intracellular wildtype
Rac1. Intriguingly, this effect became stronger when the
constitutively active and glucosylation-resistant mutant Rac1-
G12V was over-expressed. This indicates that Rac1 may be a
target of CT166 and strongly suggests that CT166 inactivates
Rac1 by glucosylation.
Our data suggest that RhoA in HeLa-CT166-wt cells was non-
glucosylated, as evidenced by sequential ADP-ribosylation. Thus,
CT166 may target Rac1 but not RhoA. Among the CGTs, several
isoforms that glucosylate Rac but not Rho are described including
lethal toxin from Clostridium sordellii [6] or Toxin B from so called
‘‘variant’’ C. difficile strains [8,24]. The determined substrate
spectrum, i.e. glucosylation of Rac1 but not RhoA, is in
accordance with the successful generation of a viable cell line
stably expressing CT166 since RhoA inactivation would have
Figure 10. Uptake of C. trachomatis serovar D is impaired by
CT166 expression. HeLa clones were infected with C. trachomatis D
(MOI 3). Chlamydial uptake by HeLa-CT166-wt, HeLa-CT166-mut, or HeLa-
control cells was determined by flow cytometry. Fluorescence intensity is
expressed as arbitrary units as described in ‘‘Material and Methods’’.
Depictedis the mean6 SDofthree independent experiments(*indicates
significant differences as compared to control cells, p,0.05) (A).
Immunofluorescence staining was performed at 24 h p.i. using anti-
chlamydia-LPS IgG-FITC (green). Cells were stained with Evans blue (red)
(B). Given is the ratio of infected cells per total cells in % in a
representative experiment, comparing infected cells that were either pre-
treated with 1 mg/ml tetracycline for 24 h (micrographs), or without.
doi:10.1371/journal.pone.0009887.g010
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division [21]. Rac1 is involved in the regulation of G1/S through
induction of cyclin D1 expression during G1 phase [25,26] and
G2/M progression through activation of the mitotic kinase Aurora
[27]. Given that CT166 glucosylates and inactivates Rac1, delayed
cell cycle progression may offer an explanation for the decreased
proliferation rate of CT166-wt-expressing cells.
HeLa-CT166-mut cells were less affected by C. trachomatis D-
induced actin-reorganization compared to control cells, similar as
HeLa-CT166-mut cells were less affected by TcdB treatment. These
results of the infection experiment are in good accordance with our
assumption that CT166 targets Rho proteins, in particular Rac1.
Given that CT166-mut binds Rac1 and temporarily prevents its
covalent modification, this observation indicates that C. trachomatis D-
induced actin re-organization includes Rac1 during infection. HeLa
cells expressing the constitutively active Rac1-G12V were protected
from C. trachomatis D-induced actin re-organization, confirming the
critical role of Rac1 in C. trachomatis D-induced actin re-organization.
Moreover, HeLa cells that were pre-treated with CNF1 were also
protected against C. trachomatis D-induced actin re-organization. These
observations suggest that the C. trachomatis D-induced cytopathic effect
is mediated by inactivation of the targeted Rho-proteins. Moreover,
these data provide direct evidence that endogenous CT166 is
translocated into the host-cell cytosol upon infection.
Chlamydial uptake was significantly impaired in CT166-wt-
expressing cells. We used flow cytometry at 2 h p.i. in addition to
the commonly used immunofluorescence staining (24 h p.i.), as
flow cytometry turned out to be more sensitive for the detection of
chlamydiae early in infection (data not shown). The results of both
techniques are in good agreement: Both types of analysis clearly
indicate that ectopic expression of CT166 diminishes chlamydial
uptake.
Actin polymerization during chlamydial entry might be
achieved involving Rac-dependent as well as -independent
pathways, similar as multiple modes of induction of actin
polymerization are observed with Salmonella. As an example,
the chlamydial effector ‘‘translocated actin recruiting phospho-
protein’’ Tarp has been identified to promote actin polymerization
by directly nucleating actin [22,28] or by activating Rac-activating
guanine nucleotide exchange factors [29]. Regarding chlamydial
entry, the requirement of Rac1 activation and actin polymeriza-
tion has been demonstrated for C. trachomatis L2 entry [30–32],
and knock-down of Rac1 (but not RhoA) decreases infectivity
determined at 24 h p.i. [33]. Rac1 (and Cdc42) was also activated
upon entry of C. caviae, a species that possesses an ORF with
homology to CGTs (consensus sequence: [4]; alignment: [2]), but
neither Rac1 (nor Cdc42) was required to initiate actin
polymerization [34]. Moreover, a subsequent decrease of Rac1
has been detected in C. caviae-infected cells [34]. In the meantime,
it turned out that the antibody which was used (clone 102) binds
only the non-glucosylated form of Rac1 [17] suggesting C. caviae-
induced Rac1 glucosylation. In this case it might be interesting to
determine the ratio of non-glucosylated Rac1 to total Rac1 in
future studies.
It has been shown that serovar D also activates Rac1 [30], but
the necessity of Rac1 activation has not been proven for the entry
of C. trachomatis serovars containing ORFs with homology to
CGTs. Our findings support the involvement of Rac1 in the
uptake of C. trachomatis D.
Our approach delivers important data about the biochemical
characterization of CT166 and its biological potential. However, it
should be noted that this characterization of CT166 is based on
over-expression of the protein. Moreover, chlamydial infections
with high MOI only, cause drastic, easily observable, general actin
re-organization and cell rounding. On the other hand, CT166
seems to be biologically highly potent, e.g. concluded from the
observation that the repressed but leaky expression system caused
already almost complete cell responses. Taking these points into
consideration it might still be justified to speculate on the
pathophysiological role of CT166 in chlamydial infection at low
MOI: The involvement of Rac1-activation in chlamydial entry
suggests the requirement of its subsequent inactivation to limit
excessive actin polymerization. Upon bacterial uptake, factors such
as the effector Salmonella protein tyrosine phosphatase (SptP)
antagonize actin polymerization by inactivating Rac (and Cdc42) in
order to rebuildhost-cell morphology afterwards [35]. Butso far,no
chlamydial effector protein has been identified that targets cellular
components which antagonize actin polymerization in order to
recover normal host-cell morphology. It is tempting to speculate
that CT166 might have a similar, locally limited, Rac1-antagoniz-
ingfunctionasSptP.ThepresenceofCT166inEBsandinthehost-
cell cytosol during the first 60 min p.i. [2] together with the
diminished uptake of chlamydiae in CT166 over-expressing HeLa
cells further support the assumption that CT166 plays a role during
the controlled entry of this pathogen.
In summary, the biological activity of CT166 was analyzed in
HeLa cells stably expressing CT166. The prominent observation
was that the actin cytoskeleton was re-organized in HeLa-CT166-
wt cells. In particular, the loss of stress fibres, lamellipodia and
filopodia and finally the loss of cell shape (cell rounding) were
observed. These morphological changes were comparable to those
observed upon treatment with TcdB, a toxin that mono-
glucosylates Rho family proteins [8]. CT166-induced actin re-
organization resembled TcdB-induced actin re-organization in
further aspects: (i) actin re-organization was prevented by either
CNF1, a broad spectrum activator of Rho proteins, or ectopic
expression of Rac1-G12V, and (ii) actin re-organization depended
on the DXD-motif present on CT166 or TcdB. The latter
observation suggests that CT166 is a glucosyltransferase, because
the DXD-motif is characteristic for mammalian and bacterial
glycosyltransferases [3,23]. Our experiments provide strong
evidence that CT166 acts as an effector protein inactivating
Rac1 but not RhoA, most likely by glucosylation, ensuring a
balanced uptake of C. trachomatis D during host-cell entry.
Materials and Methods
Cloning and Mutation of CT166
The open reading frame of CT166 was amplified by polymerase
chain reaction (PCR) using genomic DNA of C. trachomatis D/UW-
3/Cx as the template. The PCR was carried out with Pfu DNA
polymerase (Stratagene, Amsterdam, Netherlands) following the
manufacturer’s instructions. CT166 was ligated into the prokaryotic
expression plasmid pGEX-2T (GE Healthcare, UK) and the
eukaryotic expression plasmids pcDNA4
TM/TO/myc-His B (Invi-
trogen, Karlsruhe, Germany) and pCS2+MT (kindly provided by
A. Gossler, Hannover, Germany). For the creation of the
pcDNA4
TM/TO/myc-His B construct, the stop codon of CT166
was deleted in order to allow C-terminal fusion with the provided
tags. The pCS2+MT construct was created in order to obtain N-
terminalfusionwiththe6x-myc-tag.Mutagenesisofthe DXD-motif
(D415A.D417A = CT166-mut) of all constructs was carried out
using the QuickChange Site-DirectedMutagenesis Kit (Stratagene).
The integrity of all constructs was confirmed by sequencing.
Expression of Recombinant Proteins
Escherichia coli BL21 were transformed with pGEX-2T_CT166-
wt or pGEX-2T_CT166-mut. Expression was induced with IPTG
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proteins were isolated by affinity chromatography with glutathi-
one-Sepharose (Pharmacia, Germany). Then, the proteins were
recovered from the GST-tag by thrombin cleavage and
thrombin was removed by binding to benzamidine-Sepharose.
Expression was analyzed by SDS-PAGE and confirmed with mass
spectrometry.
Antiserum
One hundred micrograms of purified recombinant CT166-mut
were dissolved in 250 ml PBS and mixed with 250 ml Freund’s
complete adjuvant (Sigma). The mixture was homogenized by
sonication and administered to a rabbit by subcutaneous injection.
The antibody titer was monitored by ELISA using the recombi-
nant protein as antigen. The antiserum was pre-adsorbed to lysates
of HeLa cells that were neither infected nor transfected, and then
it was used for the detection of CT166 in Western blot analysis.
Cell Cultures
Human cervical epithelial HeLa cells (ATCC; subclone kindly
provided by R. Heilbronn, Berlin, Germany) were cultured in
Earle’s minimal essential medium (MEM) supplemented with 10%
fetal calf serum, 2 mM glutamine, 0.1 M nonessential amino
acids, and 1 mM sodium pyruvate (PAA Laboratories, Pasching,
Germany). Native cells were grown at 37uC and 5% CO2.T -
Rex
TM-HeLa cells (Invitrogen, Karlsruhe, Germany) were cul-
tured according to the manufacturer’s instructions in T-Rex
medium (MEM with 10% fetal calf serum and 5 mg/ml Blasticidin
(Invitrogen).
HeLa T-Rex Clones
HeLa T-Rex
TM cells were transfected with pcDNA4
TM/TO/
myc-His_CT166-wt or pcDNA4
TM/TO/myc-His_CT166-mut, us-
ing Magnet Assisted Transfection (Iba, Goettingen, Germany).
Stable clones were selected in the presence of 400 mg/ml Zeocin
(Invitrogen). Limiting dilution was performed in order to obtain
homogenous populations. Proper expression and inducibility with
tetracycline were verified by Western blot analysis. Homogenous
expression in the selected clones was confirmed by immunofluo-
rescence staining using mouse anti-myc (Clontech, France) and
anti-mouse IgG-FITC (DakoCytomation, Glostrup, Denmark). To
obtain cells for control experiments HeLa T-Rex cells were
transfected with pcDNA4
TM/TO/myc-His without insert. For the
analyses, one clone of each of three cell lines was combined to
obtain cell ‘‘sets’’; i.e. set 1: HeLa-CT166-wt clone JT30,
HeLa-CT166-mut clone JT4N, HeLa-control clone JT3; set 2:
HeLa-CT166-wt clone JT26, HeLa-CT166-mut clone JTB4,
HeLa-control clone JT1.
Determination of Cell Proliferation
Growth of HeLa clones was monitored by fluorescence staining
of the DNA with Hoechst 33258 (Sigma). Equal numbers of cells
were seeded on a 96-well plate for each time point. The staining
was performed with 20 mg/ml Hoechst 33258 for 30 min at 37uC
and 5% CO2. Then fluorescence was measured (355 nm/460 nm,
1.0 s) using a Victor
3 Multilabel Counter (PerkinElmer, Inc.,
Fremont, CA, USA). The corresponding number of cells was
determined in comparison to a dilution series with known cell
numbers.
Chlamydial Culture
Chlamydia trachomatis serovar D/UW-3/Cx (ATCC; VR-885)
was propagated in HeLa cells. For stock production, HeLa cell
monolayers were infected with C. trachomatis serovar D EBs by
centrifugation (55 min; 35uC; 20006g) in Panserin 401 medium
(Cytogen, Berlin, Germany) and 1 mg/ml cycloheximide (Sigma).
Infected cells were cultivated at 37uC and 5% CO2 and EBs
were harvested 2 days p.i.. The infected cells were destroyed
mechanically. Cell debris was removed by a centrifugation step
(15 min; 5006g). Then, the EBs in the supernatant were collected
by centrifugation at 22,0006g for 1 h. EBs were washed with
transport medium (1x PBS including 6.86% saccharose, 40 mg/ml
Gentamicin, 0.002% Phenol red, 2% FCS), and collected again by
centrifugation.
SDS-PAGE
Sodium dodecyl sulfate polyacrylamid gel electrophoresis was
performed with 10% polyacrylamid gels according to Maniatis’
manuals [36]. Equal amounts of protein were loaded to each lane.
The protein concentration of the lysates was determined using the
ProtaQuant-Assay Kit (Serva, Heidelberg, Germany). For a
protein standard, Precision Plus Protein Dual Color Standard
(BioRad Laboratories, USA) was used.
Western Blotting
Proteins were separated by SDS-PAGE and transferred onto a
nitrocellulose membrane for 45 min at 13 V, using the Trans-Blot
SD Semi-Dry Transfer Cell (BioRad). The membrane was blocked
for 1 h with 5% (w/v) nonfat dried milk in TBS containing 0.1%
Tween (0.1% TBST). Primary antibodies were applied over night
at 4uC as follows: anti-CT166 antiserum, diluted 1:500 in blocking
solution; mouse anti-Rac1 (Mab23A8; Millipore, Billerica, USA),
diluted 1:1000 in 0.05% TBST; mouse anti-RhoA (26C4; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), diluted 1:300 in
0.05% TBST; and mouse anti-beta-actin (AC-40, Sigma), diluted
1:2000 in 0.05% TBST. The membrane was washed and
incubated for 2 h at room temperature either with anti-rabbit
IgG-HRP (GE Healthcare), diluted 1:1000 in 0.1% TBST
containing 5% BSA, or anti-mouse IgG-HRP (MP Biomedicals,
Illkirch, France), diluted 1:2000 in 0.5% TBST containing 5%
nonfat dried milk. Then, the membrane was washed again and
developed with SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce, Rockford, IL, USA). Chemiluminescence was
detected using the Intelligent Dark Box LAS-3000 (Fujifilm Life
Science, Stamford, CT, USA).
Cytoskeletal Staining
Cells were grown on glass coverslides and processed (i.e.
infected, transiently transfected, or stimulated) as indicated. The
cells were washed with PBS and fixed with 4% paraformaldehyde
for 15 min. Cells were treated with 0.3% Triton X-100 in PBS for
5 min and blocked with 5% BSA for 60 min at room temperature.
Staining of the actin cytoskeleton was performed with rhodamine-
conjugated phalloidin (Molecular Probes, Eugene, OR, USA) for
45 min at room temperature. Subsequently, nuclei were occa-
sionally stained with DAPI in PBS containing 0.1% Tween-20 for
15 min. Coverslides were washed and mounted with Antifade
(Invitrogen). The cells were analyzed using a BX60 fluorescence
microscope (Olympus, Hamburg, Germany) or a Zeiss Axiovert
200 M (Zeiss, Goettingen, Germany).
Quantification of Actin Re-organization
Cell rounding was determined by phase contrast microscopy
(Axiovert 35; Zeiss) and given as the ratio of rounded per total
cells. The cell diameter of each cell was determined by measuring
the longest distance of the rhodamine-phalloidin-stained cells
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,30 mm were classified as ‘‘rounded’’.
Transient Transfection Experiments
For the Rho GTPase complementation experiments HeLa
clones were transfected with plasmids encoding for human RhoA-
wt, RhoA-G14V, Rac1-wt, Rac1-G12V cloned into the pEGFP-
C1 vector using FuGENEH (Roche, Basel, Switzerland), according
to the provider’s manual. Staining of the actin cytoskeleton
occurred as described above (see ‘‘Cytoskeletal Staining’’), or cells
were lysed and subjected to SDS-PAGE and Western blot
analysis. Infection of Rac1-G12V-transfected HeLa cells was
performed 24 h after transfection as described below (see
‘‘Infection Experiments’’). For analysis of HeLa cells transiently
expressing CT166-wt or CT166-mut, cells were transfected with
pCS2+MT_CT166 or pCS2+MT_CT166-D415A.D417A using
Magnet Assisted Transfection (Iba). After incubation over night at
37uC and 5% CO2, the cells were fixed with 4% paraformalde-
hyde for 5 min. The expression of the recombinant proteins was
determined by immunofluorescence using mouse anti-myc (Clon-
tech, France) and anti-mouse IgG-FITC (DakoCytomation,
Glostrup, Denmark) and staining of the actin cytoskeleton
occurred as described above (see ‘‘Cytoskeletal Staining’’).
Infection Experiments
HeLa cells were grown on glass coverslides, and further
processed prior to infection as indicated in the corresponding
text. For experiments using HeLa clones either protein expression
was induced by incubation with 1 mg/ml tetracycline for 24 h, or
cells were left untreated as indicated in the text. Infection with C.
trachomatis D occurred by centrifugation for 55 min at 35uC and
2,0006g in HeLa T-Rex medium (MOI as indicated in the text).
Since chlamydiae are susceptible to tetracycline, the cells were
rigorously washed before infection. Control infections of tetracy-
cline treated HeLa cells showed that this procedure was sufficient
to permit normal infection rates and chlamydial development
(data not shown). After centrifugation, the cells were washed again
and cultured at 37uC and 5% CO2. For determination of host-cell
morphology actin staining was performed at indicated time points
as described above (see ‘‘Cytoskeletal Staining’’). For chlamydiae
detection the infected cells were washed and fixed with methanol
at 220uC for 10 min. at 24 h p.i.. Immunofluorescence staining
was carried out with anti-chlamydia LPS IgG-FITC (DakoCyto-
mation) at 35uC for 30 min and cells were stained with Evans blue
(Sigma).
Flow Cytometry
HeLa clones were infected with MOI 3 as described above (see
‘‘Infection Experiments’’). The infected cells were trypsinized at
2 h p.i., pelleted by centrifugation, and fixed with Cellfix (BD
Biosciences). Each sample was divided in order to allow
extracellular staining and staining of total chlamydiae. Staining
of total (intracellular plus remaining extracellular) chlamydiae
occurred with anti-chlamydia LPS IgG-FITC (BioRad, Hercules,
CA, USA) after blocking and permeabilization with 3% BSA in
PBS and 0.1% saponin for 45 min on ice. PBS with 0.5% fetal calf
serum and 0.1% saponin was used for washing. Cells were fixed
with Cellfix and flow cytometry was performed using a
FACSCalibur cytometer (BD Biosciences). Control staining of
potentially extracellular chlamydiae was performed in the absence
of saponin. To determine chlamydial uptake by flow cytometry
(10.000 cells per sample) the acquired fluorescent signals from the
non-infected control was substracted from the sample of interest
to exclude nonspecific signals. The signal intensities from the
extracellular sample were substracted from the corresponding total
stained sample to determine the fluorescence signal that derived
from intracellular chlamydiae. This signal was proportionally
correlated to the whole fluorescence intensity of the performed
measurement and expressed as arbitrary units (a), whereby the
whole fluorescence intensity was set to 100.
TcdB Treatment of HeLa Cells
HeLa-CT166-mut and control cells were grown in 12-well
plates to sub-confluency and pre-treated with 1 mg/ml tetracycline
for 24 h. Then cells were incubated with 0.3 ng/ml TcdB [10] at
37uC. HeLa cells were treated with 0.3 ng/ml or 1 ng/ml TcdB
for 2 h. Staining of the actin cytoskeleton occurred as described
above (see ‘‘Cytoskeletal Staining’’), or cells were lysed and
subjected to SDS-PAGE and Western blot analysis.
CNF1 Treatment of HeLa Cells
HeLa-CT166-wt cells and control cells were grown to sub-
confluency and pre-treated with 1 mg/ml tetracycline for 24 h.
Cytotoxic necrotizing factor 1 (CNF1, kindly provided by Gudula
Schmidt, Freiburg) from E. coli was purified as previously
described [14]. Cells were incubated with 0.1 mg/ml CNF1 at
37uC for 6 h. Staining of the actin cytoskeleton occurred as
described above, or cells were lysed and subjected to SDS-PAGE
and Western blot analysis. HeLa cells were incubated with 0.1 mg/
ml CNF1 at 37uC for 6 h and proceeded to infection and
subsequent staining of the actin cytoskeleton (see above: ‘‘Infection
Experiments’’; ‘‘Cytoskeletal Staining’’).
Sequential [
32P]ADP-ribosylation Reaction
[
32P]ADP-ribosylation assay was performed as described [37].
In brief, soluble fractions of HeLa clones were incubated with C.
botulinum C3 exoenzyme in the presence of 0.3 mM[
32P]NAD
(PerkinElmer, Inc., Bosten, USA) for 30 min at 37uC. C. botulinum
C3 exoenzyme was expressed as GST-fusion protein in E. coli. The
reaction was terminated by addition of Laemmli sample buffer.
Subsequently, the samples were separated by SDS-PAGE and
subjected to PhosphoImager (Cyclone, Packard, Groningen,
Netherlands) analysis.
Statistical Analysis
Statistical evaluation of data was performed using a two-sided
Student t-test. P-values,0.05 (*) were considered statistically
significant. P-values,0.005 were indicated by two asterisks (**).
Ethics Statement and Biosafety-Consideration
According to the German gene technology law the designated
project is documented with the reference number Klos/11/
01.02.2005 and Klos/12/01.06.2005. The work was done under
biosafety level 1 conditions. A statement of the local ethics
committee is not required.
Supporting Information
Figure S1 HeLa clones express similar amounts of CT166-wt or
CT166-mut as demonstrated by Western blot, and two sets of
HeLa clones exhibit a similar phenotype. Two sets of clones of the
generated cell lines HeLa-CT166-wt and HeLa-CT166-mut and
non-expressing control cells were incubated with 1 mg/ml
tetracycline for 24 h (+) or left untreated (2). The same amount
of protein of each lysate was subjected to SDS-PAGE and
CT166 expression was analyzed by Western blot, using anti-
CT166 antiserum. Additionally, beta-actin was determined for a
loading control in set 2 (A). Application of 5 instead of 1 mg/ml
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representative Western blot analyzing one of two independent
clones for each generated cell line is depicted. The actin
cytoskeleton of two independent sets of the generated cell lines
HeLa-CT166-wt and HeLa-CT166-mut and of control cells was
stained with rhodamine-phalloidin, after 24 h incubation with
1 mg/ml tetracycline. Both CT166-wt expressing clones exhibit
actin re-organization and a rounded phenotype (HeLa clones
without tetracycline exhibit a similar phenotype; data not shown)
(C). Rounded cells (cell diameter ,30 mm) of set 2 HeLa clones
were quantified by microscopy and are presented as the ratio of
rounded cells in percent. Comparison of untreated and tetracy-
cline-treated HeLa clones reveals similar results (D). The average
cell diameter was determined in set 2 HeLa clones (E). Depicted is
the mean 6 SD of three independent experiments. (** indicates
significant difference compared to control cells, p,0.005.)
Found at: doi:10.1371/journal.pone.0009887.s001 (1.44 MB TIF)
Figure S2 HeLa clones homogenously express CT166-wt or
CT166-mut. HeLa-CT166-wt, HeLa-CT166-mut and non-ex-
pressing control cells were incubated with 1 mg/ml tetracycline for
24 h. The actin cytoskeleton was stained with rhodamine-
phalloidin. CT166-wt and CT166-mut expression was determined
by immunofluorescence detecting the C-terminal myc-tag using
mouse anti-myc and anti-mouse IgG-FITC.
Found at: doi:10.1371/journal.pone.0009887.s002 (1.72 MB TIF)
Figure S3 Cytopathic effect in HeLa cells transiently expressing
CT166. HeLa cells were transiently transfected to express myc-
tagged CT166-wt or CT166-mut. Expression of the recombinant
proteins was determined by immunofluorescence using mouse
anti-myc and anti-mouse IgG-FITC. Morphological changes of
the actin cytoskeleton stained with rhodamine-phalloidin are
already visible in low CT166 expressing HeLa cells. One
representative experiment of three is depicted.
Found at: doi:10.1371/journal.pone.0009887.s003 (2.14 MB TIF)
Figure S4 CNF1 prevents TcdB-induced morphological chang-
es in HeLa cells. HeLa cells were incubated with 15 mg/ml CNF1
from E. coli for 6 h, or with 1 ng/ml TcdB for 2 h, or with CNF1
for 6 h followed by TcdB for another 2 h, as indicated.
Found at: doi:10.1371/journal.pone.0009887.s004 (1.28 MB TIF)
Figure S5 Neither CNF1 or TcdB treatment, nor Rac1 over-
expression reduces CT166-wt expression. HeLa-CT166-wt cells
were incubated with 1 mg/ml tetracycline for 24 h. Subsequently,
cells were incubated with 15 mg/ml CNF1 from E. coli for 6 h, or
with 1 ng/ml TcdB for 2 h, or with CNF1 for 6 h followed by
TcdB for another 2 h, as indicated (A). HeLa-CT166-wt cells were
transiently transfected with the pEGFP-C1 vector encoding for
human Rac1-G12V or Rac1-wt, respectively, or the empty control
vector following incubation with 1 mg/ml tetracycline for 24 h.
Another 24 h after transfection, lysates were prepared (B). Lysates
were analyzed for CT166 expression by Western blot, using anti-
CT166 antiserum. Beta-actin was determined for a loading
control.
Found at: doi:10.1371/journal.pone.0009887.s005 (0.26 MB TIF)
Figure S6 Uptake of C. trachomatis serovar D is impaired by
CT166 expression - flow cytometry histogram supporting
Figure 10A. HeLa clones were infected with C. trachomatis serovar
D (MOI 3). Chlamydial uptake by HeLa-CT166-wt, HeLa-
CT166-mut, or HeLa-control cells was determined by flow
cytometry at 2 h p.i.. The x-axis of the depicted histograms
presents the intensity of the anti-chlamydia-FITC signal; the y-axis
presents the number of counts; grey histogram: without saponin
(extracellular staining); bold line: with saponin (extra- and
intracellular staining). The right panel (expressed as arbitrary
units) is showing the fluorescence exclusively from intracellular
chlamydiae. The calculation method allows to exclude non-
specific signals from the host-cell and from extracellular chlamyd-
iae bound to the cells surface. Depicted is one experiment as an
example for the calculation method.
Found at: doi:10.1371/journal.pone.0009887.s006 (0.11 MB TIF)
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